Download PDF
Thromb Haemost 2016; 116(06): 1122-1130
DOI: 10.1160/TH16-04-0333
Blood Cells, Inflammation and Infection
Schattauer Publishers Schattauer

Anti-VLDL receptor monoclonal antibodies inhibit fibrin-VLDL receptor interaction and reduce fibrin-dependent leukocyte transmigration

Sergiy Yakovlev
1   Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
2   Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Alexey M. Belkin
1   Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
2   Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA
6   Present address: Center for Scientific Review, National Institutes of Health, Bethesda, Maryland, USA
,
Ling Chen
3   Department of Medicine, University of Maryland School of Medicine, Baltimore, Maryland, USA
4   Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Chunzhang Cao
1   Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
4   Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Li Zhang
1   Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
4   Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Dudley K. Strickland
1   Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
4   Department of Physiology, University of Maryland School of Medicine, Baltimore, Maryland, USA
5   Department of Surgery, University of Maryland School of Medicine, Baltimore, Maryland, USA
,
Leonid Medved
1   Center for Vascular and Inflammatory Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA
2   Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, Maryland, USA
› Author Affiliations Financial support: This work was supported by National Institutes of Health R01 Grants HL056051 to L. M., HL114379 and HL120388 to D. K.S, and NS082607 to L. Z.
Further Information

Publication History

Received: 26 April 2016

Accepted after major revision: 04 June 2016

Publication Date:
09 March 2018 (online)

    Permissions and Reprints

Summary

Our previous studies revealed that the interaction of fibrin with the very low density lipoprotein receptor (VLDLR) promotes transendothelial migration of leukocytes and thereby inflammation, and localised the fibrin-binding site to CR-domains 2–4 of this receptor. In the present study, we tested interaction of three anti-VLDLR monoclonal antibodies, mAb 1H10, 1H5, and 5F3, with recombinant fragments of VLDLR containing various combinations of its CR-domains and found that the epitopes for mAb 1H10 and mAb 1H5 overlap with the fibrin-binding site of VLDLR. Based on these findings, we hypothesised that mAb 1H10 and mAb 1H5 should inhibit fibrin-VLDLR interaction and modulate leukocyte transmigration. To test this hypothesis, we first demonstrated that these monoclonal antibodies both have high affinity to the fibrin-binding fragments of the VLDL receptor and efficiently inhibit interaction between the VLDLR-binding fragment of fibrin and the fibrin-binding fragments of VLDLR. Next, in the in vitro experiments using leukocyte transendothelial migration assay we found that both monoclonal antibodies efficiently inhibit leukocyte transmigration induced by fibrin mimetic NDSK-II. Finally, in vivo experiments using mouse model of peritonitis revealed that mAb 1H10 and mAb 1H5 both significantly reduce infiltration of leukocytes into the peritoneum. Furthermore, our experiments using mouse model of myocardial ischemia-reperfusion injury revealed that both monoclonal antibodies significantly reduce myocardial injury induced by ischaemia-reperfusion. Thus, the results obtained indicate that monoclonal antibodies 1H10 and 1H5 are novel specific inhibitors of fibrin-VLDLR-dependent leukocyte transmigration pathway. They may represent potential therapeutics for treatment of fibrin-dependent inflammation including myocardial ischaemia-reperfusion injury.

Keywords

Fibrinogen/fibrin - VLDL receptor - leukocyte transmigration - monoclonal antibodies
 

  • References

  • 1 Clark RA. Fibrin and wound healing. Ann NY Acad Sci 2001; 936: 355-367.
    PubMedGoogle Scholar
  • 2 Altieri DC. Regulation of leukocyte-endothelium interaction by fibrinogen. Thromb Haemost 1999; 82: 781-786.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Petzelbauer P, Zacharowski PA, Miyazaki Y. et al. The fibrin-derived peptide Bβ15-42 protects the myocardium against ischaemia-reperfusion injury. Nat Med 2005; 11: 298-304.
    CrossrefPubMedGoogle Scholar
  • 4 Yakovlev S, Mikhailenko I, Cao C. et al. Identification of VLDLR as a novel endothelial cell receptor for fibrin that modulates fibrin-dependent transendothelial migration of leukocytes. Blood 2012; 119: 637-644.
    CrossrefPubMedGoogle Scholar
  • 5 Mosesson MW. Fibrinogen and fibrin structure and functions. J Thromb Haemost 2005; 03: 1894-1904.
    CrossrefPubMedGoogle Scholar
  • 6 Medved L, Weisel JW. on behalf of Fibrinogen and Factor XIII Subcommittee of Scientific Standardisation Committee of International Society on Thrombosis and Haemostasis. Recommendations for nomenclature on fibrinogen and fibrin. J Thromb Haemost 2009; 07: 355-359.
    CrossrefPubMedGoogle Scholar
  • 7 Blomback B, Blomback M, Henschen A. et al. N-terminal disulphide knot of human fibrinogen. Nature 1968; 218: 130-134.
    CrossrefPubMedGoogle Scholar
  • 8 Bach TL, Barsigian C, Yaen CH. et al. Endothelial cell VE-cadherin functions as a receptor for the β15-42 sequence of fibrin. J Biol Chem 1998; 273: 30719-30728.
    CrossrefPubMedGoogle Scholar
  • 9 Martinez J, Ferber A, Bach TL, Yaen CH. Interaction of fibrin with VE-cadherin. Ann NY Acad Sci 2001; 936: 386-405.
    PubMedGoogle Scholar
  • 10 Gorlatov S, Medved L. Interaction of fibrin(ogen) with the endothelial cell receptor VE-cadherin: mapping of the receptor-binding site in the NH2-terminal portions of the fibrin β chains. Biochemistry 2002; 41: 4107-4116.
    CrossrefPubMedGoogle Scholar
  • 11 Takahashi S, Kawarabayasi Y, Nakai T. et al. Rabbit very low density lipoprotein receptor: a low density lipoprotein receptor-like protein with distinct ligand specificity. Proc Natl Acad Sci USA 1992; 89: 9252-9256.
    CrossrefPubMedGoogle Scholar
  • 12 Sakai J, Hoshino A, Takahashi S. et al. Structure, chromosome location, and expression of the human very low density lipoprotein receptor gene. J Biol Chem 1994; 269: 2173-2182.
    PubMedGoogle Scholar
  • 13 Trommsdorff M, Gotthardt M, Hiesberger T. et al. Reeler/Disabled-like disruption of neuronal migration in knockout mice lacking the VLDL receptor and ApoE receptor 2. Cell 1999; 97: 689-701.
    CrossrefPubMedGoogle Scholar
  • 14 Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006; 07: 850-859.
    CrossrefPubMedGoogle Scholar
  • 15 Hembrough TA, Ruiz JF, Swerdlow BM. et al. Identification and characterisation of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 2004; 103: 3374-3380.
    CrossrefPubMedGoogle Scholar
  • 16 Takahashi S, Sakai J, Fujino T. et al. The very low-density lipoprotein (VLDL) receptor: characterisation and functions as a peripheral lipoprotein receptor. J Atheroscler Thromb 2004; 11: 200-208.
    CrossrefPubMedGoogle Scholar
  • 17 Lillis AP, Van Duyn LB, Murphy-Ullrich JE. et al. LDL receptor-related protein 1: unique tissue-specific functions revealed by selective gene knockout studies. Physiol Rev 2008; 88: 887-918.
    CrossrefPubMedGoogle Scholar
  • 18 Ruiz J, Kouiavskaia D, Migliorini M. et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res 2005; 46: 1721-1731.
    CrossrefPubMedGoogle Scholar
  • 19 Yakovlev S, Medved L. Interaction of fibrin with the very low density lipoprotein receptor: Further characterisation and localisation of the fibrin-binding site. Biochemistry 2015; 54: 4751-4761.
    CrossrefPubMedGoogle Scholar
  • 20 Yakovlev S, Gao Y, Cao C. et al. Interaction of fibrin with VE-cadherin and anti-inflammatory effect of fibrin-derived fragments. J Thromb Haemost 2011; 09: 1847-1855.
    CrossrefPubMedGoogle Scholar
  • 21 Williams SE, Ashcom JD, Argraves WS. et al. A novel mechanism for controlling the activity of α2-macroglobulin receptor/low density lipoprotein receptor-related protein. Multiple regulatory sites for 39-kDa receptor-associated protein. J Biol Chem 1992; 267: 9035-9040.
    PubMedGoogle Scholar
  • 22 Collins SJ, Ruscetti FW, Gallagher RE. et al. Terminal differentiation of human promyelocytic leukemia cells induced by dimethyl sulfoxide and other polar compounds. Proc Natl Acad Sci USA 1978; 75: 2458-2462.
    CrossrefPubMedGoogle Scholar
  • 23 Cao C, Lawrence DA, Strickland DK. et al. A specific role of integrin Mac-1 in accelerated macrophage efflux to the lymphatics. Blood 2005; 106: 3234-3241.
    CrossrefPubMedGoogle Scholar
  • 24 Hauert AB, Martinelli S, Marone C. et al. Differentiated HL-60 cells are a valid model system for the analysis of human neutrophil migration and chaemotaxis. Int J Biochem Cell Biol 2002; 34: 838-854.
    CrossrefPubMedGoogle Scholar
  • 25 Herz J, Goldstein JL, Strickland DK. et al. 39-kDa protein modulates binding of ligands to low density lipoprotein receptor-related protein/α2-macroglobulin receptor. J Biol Chem 1991; 266: 21232-21238.
    PubMedGoogle Scholar
  • 26 Yakovlev S, Gorlatov S, Ingham K. et al. Interaction of fibrin(ogen) with heparin: further characterisation and localisation of the heparin-binding site. Biochemistry 2003; 42: 7709-7716.
    CrossrefPubMedGoogle Scholar